Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity

  • Tejal Rawal
  • Neha Mishra
  • Abhishek Jha
  • Apurva Bhatt
  • Rajeev K. Tyagi
  • Shital Panchal
  • Shital Butani
Research Article
  • 2 Downloads

Abstract

The elevated blood levels of cholesterol and low-density lipoproteins result in hyperlipidemia. The available expensive prophylactic treatments are kindred with severe side effects. Therefore, we fabricated the polymeric nanoparticles of gamma-oryzanol to achieving the improved efficacy of drug. The nanoparticles were prepared by ionic gelation method and optimized using 23 full factorial design taking drug/polymer ratio (X1), polymer/cross linking agent ratio (X2), and stirring speed (X3) as independent variables. The average particle size, percentage entrapment efficiency, and in vitro drug release at 2, 12, and 24 h were selected as response parameters. The factorial batches were statistically analyzed and optimized. The optimized nanoparticles were characterized with respect to particle size (141 nm) and zeta potential (+ 6.45 mV). Results obtained with the prepared and characterized formulation showed 83% mucoadhesion towards the intestinal mucosa. The in vitro findings were complemented well by in vivo anti-hyperlipidemic activity of developed formulation carried out in Swiss albino mouse model. The in vivo studies showed improved atherogenic index, malondialdehyde, and superoxide dismutase levels in poloxamer-407-induced hyperlipidemic animals when treated with oryzanol and gamma-oryzanol nanoformulation. Based on our findings, we believe that chitosan-mediated delivery of gamma-oryzanol nanoparticles might prove better in terms of anti-hyperlipidemic therapeutics.

KEY WORDS

gamma-oryzanol chitosan nanoparticles poloxamer-407 atorvastatin 

Notes

Acknowledgements

The authors would like to thank Institute of Pharmacy, Nirma University, Ahmedabad for providing us all the facilities to carry out our research work.

Compliance with Ethical Standards

The animal protocol was approved by the Institutional Animal Ethics Committee (Protocol no. IP/PCEU/MPH/14-1/010). All animals were treated in accordance with the guidelines of the committee for CPCSEA.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clinics in Office Practice [Internet]. 2013 [cited 2017 Aug 23];40:195–211. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0095454312000991
  2. 2.
    Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann NutrMetab. 2009;55:368–74.Google Scholar
  3. 3.
    Zhang J, Zhang W, Mamadouba B, Xia W. A comparative study on hypolipidemic activities of high and low molecular weight chitosan in rats. Int J Biol Macromolecules [Internet]. 2012 [cited 2017 Nov 20];51:504–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0141813012002346
  4. 4.
    Zavoshy R, Noroozi M, Jahanihashemi H. Effect of low calorie diet with rice bran oil on cardiovascular risk factors in hyperlipidemic patients. J Res Med Sci. 2012;17:626–31.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Cicero AF, Gaddi A. Rice bran oil and gamma-oryzanol in the treatment of hyperlipoproteinaemias and other conditions. Phytother Res. 2001;15:277–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Ghatak SB, Panchal SJ. Anti-hyperlipidemic activity of oryzanol, isolated from crude rice bran oil, on Triton WR-1339-induced acute hyperlipidemia in rats. RevistaBrasileira de Farmacognosia [Internet]. 2012 [cited 2017 Nov 20];22:642–8. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2012000300024&lng=en&nrm=iso&tlng=en
  7. 7.
    Cho J-Y, Lee HJ, Kim GA, Kim GD, Lee YS, Shin SC, et al. Quantitative analyses of individual γ-Oryzanol (Steryl Ferulates) in conventional and organic brown rice (Oryza sativa L.). J Cereal Sci [Internet]. 2012 [cited 2017 Aug 23];55:337–43. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0733521012000173
  8. 8.
    Plapied L, Duhem N, des Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci [Internet]. 2011 [cited 2017 Aug 23];16:228–37. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1359029411000033
  9. 9.
    Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm [Internet]. 2007 [cited 2017 Aug 23];65:259–69. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0939641106003316
  10. 10.
    Ghaderi S, Ghanbarzadeh S, Mohammadhassani Z, Hamishehkar H. Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products. Tabriz University of Medical Sciences; 2014 p.Google Scholar
  11. 11.
    Seetapan N, Bejrapha P, Srinuanchai W, Ruktanonchai UR. Rheological and morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid nanoparticles (SLNs). Micron [Internet]. 2010 [cited 2018 Feb 6];41:51–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S096843280900122X
  12. 12.
    Viriyaroj A, Ngawhirunpat T, Sukma M, Akkaramongkolporn P, Ruktanonchai U, Opanasopit P. Physicochemical properties and antioxidant activity of gamma-oryzanol-loaded liposome formulations for topical use. Pharm Dev Technol [Internet]. 2009 [cited 2018 Feb 6];14:665–71. Available from: http://www.tandfonline.com/doi/full/10.3109/10837450902911937, 14, 665, 671
  13. 13.
    Manosroi A, Chutoprapat R, Abe M, Manosroi W, Manosroi J. Transdermal absorption enhancement of rice bran bioactive compounds entrapped in niosomes. AAPS Pharm Sci Tech [Internet]. 2012 [cited 2018 Feb 6];13:323–35. Available from: http://www.springerlink.com/index/10.1208/s12249-012-9751-1
  14. 14.
    Sapino S, Carlotti ME, Cavalli R, Ugazio E, Berlier G, Gastaldi L, et al. Photochemical and antioxidant properties of gamma-oryzanol in beta-cyclodextrin-based nanosponges. J Incl Phenom Macrocycl Chem [Internet]. 2013 [cited 2018 Feb 6];75:69–76. Available from: http://link.springer.com/10.1007/s10847-012-0147-3
  15. 15.
    Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med [Internet]. 2005 [cited 2018 Feb 6];172:1487–90. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.200504-613PP
  16. 16.
    Ghosh PK. Hydrophilic polymeric nanoparticles as drug carriers. Indian J Biochem Biophys. 2000;37:273–82. Available from:http://nopr.niscair.res.in/bitstream/123456789/19833/1/IJBB%2037%285%29%20273-282.pdf
  17. 17.
    Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res [Internet]. 2004 [cited 2018 Feb 6];339:2693–700. Available from: http://linkinghub.elsevier.com/retrieve/pii/S000862150400388X
  18. 18.
    Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull. 2010;58:1423–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B: Biointerfaces [Internet]. 2012 [cited 2017 Nov 20];90:21–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0927776511005650
  20. 20.
    Yadav R, Kumar D, Kumari A, Yadav SK. Encapsulation of podophyllotoxin and etoposide in biodegradable poly-d, l-lactide nanoparticles improved their anticancer activity. J Microencapsul [Internet]. 2014 [cited 2017 Nov 20];31:211–9. Available from: http://www.tandfonline.com/doi/full/10.3109/02652048.2013.834988, 31, 211, 219
  21. 21.
    Rajitha P, Gopinath D, Biswas R, Sabitha M, Jayakumar R. Chitosan nanoparticles in drug therapy of infectious and inflammatory diseases. Expert Opin Drug Deliv [Internet]. 2016 [cited 2017 Nov 20];13:1177–94. Available from: http://www.tandfonline.com/doi/full/10.1080/17425247.2016.1178232, 13, 1177, 1194
  22. 22.
    Paolicelli P, de la Fuente M, Sánchez A, Seijo B, Alonso MJ. Chitosan nanoparticles for drug delivery to the eye. Expert Opin Drug Deliv [Internet]. 2009 [cited 2017 Nov 20];6:239–53. Available from: http://www.tandfonline.com/doi/full/10.1517/17425240902762818, 6, 239, 253
  23. 23.
    Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release [Internet]. 2004 [cited 2017 Nov 20];100:5–28. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365904003803
  24. 24.
    Bucci R, Magrì AD, Magrì AL, Marini F. Comparison of three spectrophotometric methods for the determination of γ-oryzanol in rice bran oil. Anal Bioanal Chem [Internet]. 2003 [cited 2017 Nov 20];375:1254–9. Available from: http://link.springer.com/10.1007/s00216-002-1700-5, 375, 1254, 1259
  25. 25.
    Guan J, Cheng P, Huang SJ, Wu JM, Li ZH, You XD, et al. Optimized preparation of levofloxacin-loaded chitosan nanoparticles by ionotropic gelation. Physics Procedia [Internet]. 2011 [cited 2017 Nov 20];22:163–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1875389211006808
  26. 26.
    Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci [Internet]. 2014 [cited 2017 Nov 20];4:189–97. Available from: http://link.springer.com/10.1007/s13204-012-0188-3, 4, 189, 197
  27. 27.
    Dong Y, Ng WK, Hu J, Shen S, Tan RBH. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int J Pharm [Internet]. 2010 [cited 2017 Nov 20];386:256–61. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517309008072
  28. 28.
    Rawal T, Parmar R, Tyagi RK, Butani S. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf B: Biointerfaces [Internet]. 2017 [cited 2017 Nov 29];154:321–30. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0927776517301625
  29. 29.
    Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3:207–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine: Nanotechnol, Biol Med [Internet]. 2010 [cited 2017 Nov 20];6:662–71. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1549963410000961
  31. 31.
    Araujo FB, Barbosa DS, Hsin CY, Maranhão RC, Abdalla DS. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis. 1995;117:61–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Acay A, Ulu MS, Ahsen A, Ozkececi G, Demir K, Ozuguz U, et al. Atherogenic index as a predictor of atherosclerosis in subjects with familial Mediterranean fever. Medicina [Internet]. 2014 [cited 2017 Nov 20];50:329–33. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1010660X14001153
  33. 33.
    Johnston TP, Zhou X. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect: J Cardiovasc Pharmacol [Internet]. 2007 [cited 2017 Nov 20];49:246–52. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005344-200704000-00009
  34. 34.
    Yasuda T, Johnston TP, Shinohara M, Inoue M, Ishida T. The effect of poloxamer 407 on the functional properties of HDL in mice: P-407 mouse model of dysfunctional HDL. J Pharm Pharmacol [Internet]. 2012 [cited 2017 Nov 20];64:677–87. Available from: http://doi.wiley.com/10.1111/j.2042-7158.2011.01444.x
  35. 35.
    Swapnil SA, Anup BT, Ashok B, Ravishankar B, Shukla V. Evaluation of anti-hyperlipidemic activity of LekhanaBasti in albino rats. AYU (An International Quarterly Journal of Research in Ayurveda) [Internet]. 2013 [cited 2018 Feb 9];34:220. Available from: http://www.ayujournal.org/text.asp?2013/34/2/220/119687
  36. 36.
    Owens AP, Byrnes JR, Mackman N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends in Cardiovascular Medicine [Internet]. 2014 [cited 2018 Feb 9];24:95–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S105017381300114X
  37. 37.
    Kim J-A, Kim J-E, Song SH, Kim HK. Influence of blood lipids on global coagulation test results. Annals of Laboratory Medicine [Internet]. 2015 [cited 2018 Feb 9];35:15. Available from: https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2015.35.1.15, 35, 15, 21
  38. 38.
    Lundquist P, Artursson P. Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Advanced Drug Delivery Reviews [Internet]. 2016 [cited 2017 Nov 20];106:256–76. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0169409X16302277
  39. 39.
    Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release [Internet]. 2001 [cited 2018 Feb 9];70:353–63. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365900003679
  40. 40.
    Chen J, Liu C, Shan W, Xiao Z, Guo H, Huang Y. Enhanced stability of oral insulin in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin. J Microencapsul [Internet]. 2015 [cited 2018 Feb 6];32:632–41. Available from: http://www.tandfonline.com/doi/full/10.3109/02652048.2015.1065920, 32, 632, 641
  41. 41.
    Fan T, Chen C, Guo H, Xu J, Zhang J, Zhu X, et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm [Internet]. 2014 [cited 2018 Feb 6];88:518–28. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0939641114002033
  42. 42.
    Pathak L, Kanwal A, Agrawal Y. Curcumin loaded self assembled lipid-biopolymer nanoparticles for functional food applications. J Food Sci Technol [Internet]. 2015 [cited 2018 Feb 14];52:6143–56. Available from: http://link.springer.com/10.1007/s13197-015-1742-2, 52, 6143, 6156
  43. 43.
    Gohel MC, Bariya SH. Fabrication of triple-layer matrix tablets of venlafaxine hydrochloride using xanthan gum. AAPS Pharm Sci Tech [Internet]. 2009 [cited 2018 Feb 14];10:624–30. Available from: http://www.springerlink.com/index/10.1208/s12249-009-9244-z
  44. 44.
    Sakloetsakun D, Perera G, Hombach J, Millotti G, Bernkop-Schnürch A. The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate. AAPS PharmSciTech [Internet]. 2010 [cited 2018 Feb 7];11:1185–92. Available from: http://www.springerlink.com/index/10.1208/s12249-010-9479-8
  45. 45.
    Bhosale UV, Kusum Devi V, Jain N. Formulation and optimization of mucoadhesive nanodrug delivery system of acyclovir. J Young Pharmacists [Internet]. 2011 [cited 2018 Feb 7];3:275–83. Available from: http://www.jyoungpharm.org/article/559
  46. 46.
    Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev [Internet]. 2006 [cited 2017 Nov 20];58:1688–713. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0169409X06001840
  47. 47.
    Chaudhary HR, Brocks DR. The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines. J Pharm Pharm Sci. 2013;16:65–73.CrossRefPubMedGoogle Scholar
  48. 48.
    Sarker M, Mahmud ZA, Saha SK, Tithi NS, Ali MS, Bachar SC. Anti hyperlipidemic activity of flowers of Punica granatum in poloxamer-407 induced hyperlipidemic mice model. Pharmacogn J [Internet]. 2012 [cited 2017 Nov 20];4:66–70. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0975357512800241
  49. 49.
    Korolenko T, Johnston TP, Dubrovina NI, Kisarova YA, Zhanaeva SY, Cherkanova MS, et al. Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice. Interdisc Toxicol [Internet]. 2013 [cited 2017 Nov 20];6. Available from: http://www.degruyter.com/view/j/intox.2013.6.issue-1/intox-2013-0004/intox-2013-0004.xml
  50. 50.
    Omari-Siaw E, Wang Q, Sun C, Gu Z, Zhu Y, Cao X, et al. Tissue distribution and enhanced in vivo anti-hyperlipidemic-antioxidant effects of perillaldehyde-loaded liposomal nanoformulation against Poloxamer 407-induced hyperlipidemia. Int J Pharm [Internet]. 2016 [cited 2017 Nov 20];513:68–77. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517316307839
  51. 51.
    Ghatak SB, Dhamecha PS, Bhadada SV, Panchal SJ. Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. Eur J Pharmacol [Internet]. 2011 [cited 2017 Nov 20];659:213–23. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0014299911003414

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Tejal Rawal
    • 1
  • Neha Mishra
    • 1
  • Abhishek Jha
    • 1
  • Apurva Bhatt
    • 1
  • Rajeev K. Tyagi
    • 2
    • 3
  • Shital Panchal
    • 1
  • Shital Butani
    • 1
  1. 1.Department of Pharmaceutical Technology, Institute of PharmacyNirma UniversityAhmedabadIndia
  2. 2.Institute of ScienceNirma UniversityAhmedabadIndia
  3. 3.Department of Periodontics, College of Dental MedicineGeorgia Regents UniversityAugustaUSA

Personalised recommendations